I

Iovance Biotherapeutics

TIL-based T-cell therapies for solid tumors

Aseptic Manufacturing Technician 1

ContractPosted on 10/27/2026
No salary listed
Entry
Bachelor's
Philadelphia, PA, USA
In PersonOnsite manufacturing role; rotating shifts may include weekends, evenings, and holidays.
Biology & BiotechBioprocess & Biomanufacturing

About the job

Requirements
  • A bachelor's degree or equivalent experience is required.
  • Minimum 0–1 year of experience in biopharmaceutical-based Good Manufacturing Practices manufacturing operations, including aseptic technique, aseptic liquid transfers, use of welders and sealers, biosafety cabinet aseptic operations, and associated downstream processing; this experience is described as a plus.
  • Must be able to read, write, and understand English, especially for Good Documentation Practices.
  • Proficiency in Microsoft Excel, Word, Outlook, and Teams.
  • Ability to accurately and reproducibly perform arithmetic calculations, including fractions, decimals, and percentages, and basic algebraic and geometric calculations.
  • May work on moderately complex assignments requiring judgment to resolve operational issues without negatively impacting manufacturing efforts.
  • Quality mindset and familiarity with 21 CFR Part 11, standard GxP best practices, and FDA regulations.
  • Must be able to pass and maintain gowning qualification.
  • Must comply with safety standard operating procedures, safety data sheets, laboratory procedures, company policy, and Occupational Safety and Health Administration regulations.
  • Must pass a vision exam for the Visual Inspection Program: not color blind; corrected or uncorrected 20/20 near vision in both eyes; and clarity of near- and mid-range vision, depth perception, and ability to identify and distinguish colors.
  • Must be able to wear cleanroom attire and personal protective equipment, including scrubs, gowning coveralls, masks, and gloves.
  • Must meet requirements for and be able to wear a half-face respirator when using hazardous chemicals.
  • Must be able to stand or walk 90% of the scheduled workday and sit 10%, potentially including climbing ladders or steps; crouch, bend, twist, reach, perform repetitive motions, and lift and carry objects weighing 50 pounds.
  • Must be able to work in office and manufacturing settings, including cleanroom work with chemical or biochemical exposures while using appropriate personal protective equipment, and potential exposure to noise, equipment hazards, and strong odors.
  • Must be able to handle multiple priorities and meet deadlines.
Responsibilities
  • Develop a comprehensive understanding of and proficiently execute the company's Good Manufacturing Practices cell therapy manufacturing processes.
  • Complete training sessions and maintain training documentation.
  • Understand and comply with documented quality standards and requirements.
  • Follow Good Manufacturing Practices, standard operating procedures, and Good Documentation Practices.
  • Provide operational support through materials stocking and transfer, kit preparation, room readiness, equipment cleaning, and inventory transactions using electronic inventory systems.
  • Transfer materials; receive tumors; complete Chain of Information and Chain of Custody transactions; incubate materials; retrieve feeder cells from liquid nitrogen tanks; perform final product visual inspection; and cryopreserve final products in controlled-rate freezers.
  • Perform assigned biosafety cabinet runner duties, balance weight checks and operation, operate liquid repeater pumps, operate tube sealers and welders, and use incubators for cell culture.
  • Perform in-suite environmental monitoring on process days and document environmental monitoring duties using the sample management electronic system.
  • Review logbooks.
  • Attend the daily Tier 1 meeting and escalate issues and concerns to Area Management for further investigation.
  • Adhere to production schedules while maintaining internal production priorities.
  • Work assigned schedules, which may require overtime, weekends, evenings, and holidays; initial onboarding training occurs on regular weekday first-shift hours, after which assignment may be to day or night shifts.
  • Perform other duties as assigned.
Desired Qualifications
  • Background in cell culture, aseptic gowning and qualifications, and ISO Class 5 (Grade A) cleanroom operations is strongly desired.
  • Ability to build relationships quickly and credibly.
  • Ability to work successfully in a fast-paced, team-oriented environment and manage constant change.

About the company

I

Iovance Biotherapeutics

View
Website

Iovance Biotherapeutics develops cancer immunotherapies using Tumor Infiltrating Lymphocytes (TIL). It harvests T cells from a patient’s tumor, expands them in the lab, and infuses them back into the patient to attack solid tumors. The therapies are designed as single-treatment treatments without the need for ongoing maintenance. The company differentiates itself by focusing on TIL-based adoptive cell therapy with broad antigen targeting and dedicated cell therapy manufacturing capabilities, including the Iovance Cell Therapy Center (iCTC) to scale production. Its goal is to develop, manufacture, and commercialize proprietary TIL therapies and expand access to cell-based cancer treatments through partnerships and scaled production.

Company Size

501-1,000

Company Stage

IPO

Headquarters

San Carlos, California

Founded

2007

Get referred to Iovance Biotherapeutics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • September 29, 2026 revenue guidance rose to $410 million–$420 million for 2026.
  • October 1, 2026 CMO Noah Berkowitz strengthens late-stage development and regulatory execution.
  • Fast Track programs in lung, sarcoma, and endometrial cancer expand the addressable market.

What critics are saying

  • Amtagvi remains the only real commercial engine; a slowdown breaks the whole thesis.
  • 2025 securities and derivative litigation still hangs over management through 2026.
  • Manufacturing complexity and center adoption bottlenecks can delay volume growth into 2027.

What makes Iovance Biotherapeutics unique

  • Amtagvi became FDA-approved in 2024, validating Iovance’s autologous TIL platform.
  • Philadelphia iCTC centralizes manufacturing, giving Iovance control over supply and margins.
  • Iovance pairs one-time TIL treatment with expanding authorized centers across multiple countries.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Remote Work Options

Growth & Insights and Company News

6 month growth

0%

1 year growth

0%

2 year growth

4%
Healthcare Industry Today
Oct 6th, 2026
AVBCC recognizes Iovance Biotherapeutics' Dr. Fred Vogt with inaugural Global Cancer Research & Innovation Award.

AVBCC recognizes Iovance Biotherapeutics' Dr. Fred Vogt with inaugural Global Cancer Research & Innovation Award. AVBCC has presented its Global Cancer Research & Innovation Award to Fred Vogt, PhD, JD, Interim CEO, President, and General Counsel, Iovance Biotherapeutics. Dr. Vogt's extraordinary blend of scientific leadership, strategic vision, and unwavering commitment to advancing breakthrough therapies embodies the spirit of innovation and impact this award honors." - Burt Zweigenhaft, PhD, DLitt NEW YORK, NY, UNITED STATES, October 6, 2026 / EINPresswire.com / - The Association for Value-Based Cancer Care (AVBCC) is pleased to announce Fred Vogt, PhD, JD, Interim CEO, President, and General Counsel, Iovance Biotherapeutics, as the recipient of its inaugural Global Cancer Research & Innovation Award. Presented to Dr. Vogt today at AVBCC's 2nd Annual Global Cancer Research & Innovation Symposium (GCRIS), this award recognizes his visionary leadership and contributions to advancing innovation in oncology. Now in its second year, AVBCC's GCRIS serves as a catalyst for advancing the future of cancer care by convening leading experts to explore breakthrough science, emerging therapies, and highlight innovations transforming cancer treatment worldwide. "The Global Cancer Research & Innovation Award is a reflection of AVBCC's commitment to celebrating the individuals and organizations driving progress across the oncology innovation ecosystem," says Burt Zweigenhaft, PhD, DLitt, Executive Director and Founder, AVBCC. "Dr. Vogt's extraordinary blend of scientific leadership, strategic vision, and unwavering commitment to advancing breakthrough therapies embodies the spirit of innovation and impact that this award was created to honor." "I am deeply honored to receive the inaugural Global Cancer Research & Innovation Award from the Association for Value-Based Cancer Care," says Dr. Vogt. "This recognition reflects the dedication of the entire Iovance team to make the promise of TIL therapy a reality for patients with advanced melanoma. The approval and launch of Amtagvi (R) underscored the potential for cell therapy to fundamentally change the treatment landscape for solid tumor cancers, and I'm grateful to the Association for championing innovation that ultimately benefits the patients who need it most." In 2024, Dr. Vogt led Iovance through one of the most significant milestones in modern oncology with the FDA approval and commercial launch of Amtagvi (R)(lifileucel), the first cell therapy ever approved for a solid tumor. This achievement opened an entirely new category of cancer treatment for patients with advanced melanoma and underscores the broader scientific and organizational progress he has championed. At Iovance's helm, Dr. Vogt has overseen the development of its end-to-end manufacturing infrastructure and commercial transformation including the acquisition and integration of Proleukin (R)- a decision that strengthened Iovance's ability to support the TIL therapy regimen. Additionally, he has spent more than 25 years advancing breakthrough cancer therapies across the industry, contributing to the approvals of Hycamtin (R), Votrient (R), Tafinlar (R), Mekinist (R), and Arzerra (R). With a rare dual background as both scientist and business leader, Dr. Vogt embodies the entrepreneurship, integrity, and patient centered commitment recognized by this award. About the Association for Value-Based Cancer Care (AVBCC) AVBCC is a 501(c)(6) educational organization dedicated to fostering the exchange of knowledge among stakeholders across the cancer care ecosystem who are responsible for ensuring that optimal care and access are delivered to all patients with cancer. Its goal is to inform, educate, and foster exchange of current and future state information between all stakeholders: Oncologists and Hematologists, Nurses, Oncology Nurse Navigators, Pathologists and Geneticists, Pharmacists, Practice Administrators, Practice Managers, Patient Advocacy Organizations, Managed Care Organizations, Insurance Companies, Third-Party Payers, Integrated Health Delivery Systems, Cancer Centers of Excellence, Medical Directors, Pharmacy Directors, Pharmaceutical and Biotech Manufacturers, Personalized Medicine Providers, Researchers, and, of course, cancer patients. Visit AVBCC.org to learn more about its organization and offerings. About Iovance Biotherapeutics Iovance Biotherapeutics, Inc. is the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid tumors. Amtagvi (R)(lifileucel) is the first FDA-approved, one-time treatment for previously treated advanced melanoma, now approved in three global markets and available at nearly 100 authorized treatment centers (ATCs). The Iovance TIL platform spans registrational trials and next-generation programs in additional solid tumors, including gene-edited and IL-12 tethered TIL therapies, next-generation IL-2, and precision immuno-oncology approaches. As the first and only company to take TIL therapy from concept to a broadly accessible commercial treatment, Iovance operates as an end-to-end cell therapy company, anchored by fully owned, centralized U.S.-based manufacturing that is scaled to serve thousands of cancer patients worldwide each year. Headquartered in Pennsylvania with offices and laboratories in California and Florida, Iovance serves patients at ATCs and clinical sites across almost the entire U.S. and in many countries around the world. For more information, please visit www.iovance.com. Amtagvi (R) and its accompanying design marks, Proleukin (R), Iovance (R), and IovanceCares(TM) are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners. Information on Iovance's broad, industry-leading patent portfolio is available on the Intellectual Property page on www.iovance.com. Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. Healthcare Industry Today do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Yahoo Finance
Oct 4th, 2026
Iovance soars 256% on upgraded 2026 revenue guidance of $410M–$420M

Iovance Biotherapeutics became the top-performing mid-cap stock in the US market in Q3, with shares soaring 256%. The rally was driven by raised 2026 revenue guidance of $410 million to $420 million, representing 56% to 60% growth from 2025's $263 million. The company's optimism stems from strong demand for cancer treatments Amtagvi and Proleukin. In Q2, Iovance reported net revenues of $99 million, up 66% year-on-year, with $91 million from Amtagvi and $9 million from Proleukin. Amtagvi is the first FDA-approved individualised T-cell therapy for solid tumour cancer, specifically treating unresectable or metastatic melanoma. It has received regulatory approval in the US, Canada, and Australia. Analysts responded positively, with HC Wainwright raising its price target to $20 from $9 and Goldman Sachs assigning a $15 target.

Yahoo Finance
Oct 1st, 2026
Iovance appoints Noah Berkowitz as chief medical officer to advance TIL therapies

Iovance Biotherapeutics has appointed Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer, effective 30 September 2026. The Philadelphia-based biotechnology company develops tumour infiltrating lymphocyte therapies for cancer patients. Berkowitz previously served as Chief Medical Officer at Arvinas Pharmaceuticals, where he led the clinical strategy resulting in the first FDA approval of a targeted protein degradation therapy. Before that, he held senior positions at Bristol Myers Squibb, overseeing development teams that achieved regulatory approvals for CAR T cell therapies Abecma and Breyanzi. In connection with the appointment, Iovance granted Berkowitz inducement stock options and restricted stock units covering up to 450,000 shares at an exercise price of $14.82. The awards vest over three years.

GlobeNewswire
Oct 1st, 2026
Iovance Biotherapeutics appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer.

Iovance Biotherapeutics appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer. Leader in Global Drug Development of T Cell Therapies PHILADELPHIA, Oct. 01, 2026 (GLOBE NEWSWIRE) - Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced the appointment of Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer (CMO), effective September 30, 2026. "We are pleased to welcome Noah to Iovance as we prepare for important development and regulatory milestones for our TIL platform across multiple solid tumor cancers," said Frederick Vogt, Ph.D., J.D., Interim President and Chief Executive Officer. "Noah brings deep experience in global drug development that has led to regulatory approvals across cancer, blood disorders, and cell therapy. His track record will be instrumental as we work to bring TIL therapy to many more patients in new markets, earlier treatment settings, and additional solid tumor cancers." As Chief Medical Officer of Arvinas Pharmaceuticals, Dr. Berkowitz led the clinical strategy that resulted in the first-ever U.S. Food and Drug Administration (FDA) approval of a targeted protein degradation therapy and expanded the company's clinical programs across cancer, neurological, and rare diseases. Previously, Dr. Berkowitz served as Senior Vice President and Therapeutic Area Head, Hematology at Bristol Myers Squibb, where he oversaw the full scope of drug development for the company's benign and malignant hematology programs and, on an interim basis, its cell therapy programs. His global development teams achieved regulatory approvals for the chimeric antigen receptor (CAR) T cell therapies Abecma and Breyanzi, two of the first cell therapies approved for multiple myeloma and large B cell lymphoma, respectively. Clinical programs under his leadership helped drive recent annual sales of Reblozyl above $2 billion. Earlier, Dr. Berkowitz held leadership positions of increasing responsibility in clinical development across multiple cancer indications at Novartis. Dr. Berkowitz completed a clinical investigation fellowship in medical oncology at the National Cancer Institute (NCI). He holds an M.D. and Ph.D. in molecular immunology from Columbia University. "I am excited to join Iovance at this critical inflection point to explore broader applications for TIL technology in new indications and treatment settings," stated Dr. Berkowitz. "The Iovance TIL platform demonstrates remarkable clinical results and represents the new frontier across solid tumors, including next-generation approaches. I look forward to contributing to the Iovance vision to expand the reach of this transformative treatment to patients who need it most." In connection with Dr. Berkowitz's appointment, Iovance approved the grant of inducement stock options and restricted stock units covering an aggregate of up to 450,000 shares of Iovance's common stock to Dr. Berkowitz. The awards were granted on September 30, 2026 (the date of grant), under Iovance's Amended and Restated 2021 Inducement Plan, which provides for the granting of equity awards to new employees of Iovance by the Company's compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4). Each of the stock options granted has an exercise price of $14.82, the closing price of Iovance's common stock on the date of grant. Each stock option and each restricted stock unit vests over a three-year period, with one-third of the shares vesting on the first anniversary of Dr. Berkowitz's start date (the first vesting date) and the remaining shares vesting in eight quarterly installments over the next two years, commencing with the first quarter following the first vesting date. In addition, certain of these restricted stock units may vest upon the achievement of performance milestones based on specified regulatory results rather than time-based vesting. The foregoing vesting is subject to continued employment with Iovance through the applicable vesting dates. About Iovance Biotherapeutics, Inc. Iovance Biotherapeutics, Inc. is the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid tumors. Amtagvi(R)(lifileucel) is the first FDA-approved, one-time treatment for previously treated advanced melanoma, now approved in three global markets and available at nearly 100 authorized treatment centers (ATCs). The Iovance TIL platform spans registrational trials and next-generation programs in additional solid tumors, including gene-edited and IL-12 tethered TIL therapies, next-generation IL-2, and precision immuno-oncology approaches. As the first and only company to take TIL therapy from concept to a broadly accessible commercial treatment, Iovance operates as an end-to-end cell therapy company, anchored by fully owned, centralized U.S.-based manufacturing that is scaled to serve thousands of cancer patients worldwide each year. Headquartered in Pennsylvania with offices and laboratories in California and Florida, Iovance serves patients at ATCs and clinical sites across almost the entire U.S. and in many countries around the world. For more information, please visit www.iovance.com. Amtagvi(R) and its accompanying design marks, Proleukin(R), Iovance(R), and IovanceCares(TM) are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners. Information on Iovance's broad, industry-leading patent portfolio is available on the Intellectual Property page on www.iovance.com. Forward-Looking Statements Certain matters discussed in this press release are "forward-looking statements" of Iovance Biotherapeutics, Inc. (hereinafter referred to as the "Company," "we," "us," or "our") within the meaning of the Private Securities Litigation Reform Act of 1995 (the "PSLRA"). Without limiting the foregoing, we may, in some cases, use terms such as "predicts," "believes," "potential," "achievable," "continue," "estimates," "anticipates," "expects," "plans," "intends," "forecast," "guidance," "outlook," "may," "can," "could," "might," "will," "should," or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments, and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements, and developments to be materially different from those expressed in or implied by these forward-looking statements. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in our filings with the U.S. Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Investors [email protected] 650-260-7120 ext. 150 Media [email protected] 650-260-7120 ext. 150

Asianet News
Sep 29th, 2026
IOVA stock hits over 2-year highs - why Iovance raised its FY2026 revenue outlook.

IOVA stock hits over 2-year highs - why Iovance raised its FY2026 revenue outlook. Published: Sep 29 2026, 08:10 PM IST * FB * TW * Linkdin * Whatsapp * GNFollow Us Iovance raised its 2026 revenue forecast due to strong U.S. demand for Amtagvi and Proleukin cancer therapies. * Iovance expects FY 2026 revenue of $410 million to $420 million, up from $350 million to $370 million. * The company is expected to report its Q3 results in November. * Lifileucel is being developed beyond its current melanoma use, including programs in lung and endometrial cancers. Shares of Iovance Biotherapeutics (IOVA) surged to their highest levels in more than two years on Tuesday, after the biotech firm raised its full-year revenue outlook, citing stronger U.S. demand for its cancer treatments. At the time of writing, IOVA stock was up more than 25% and heading for its fourth monthly gain in five months. Why did Iovance raise its guidance? Iovance said it expects full-year 2026 revenue of $410 million to $420 million, up from its previous $350 million to $370 million forecast. The new midpoint is $55 million higher and implies nearly 60% annual growth, it said. The increased outlook follows a record second quarter. Iovance reported $99.3 million in second-quarter (Q2) product revenue, including $89.5 million from Amtagvi (lifileucel) and $9.8 million from Proleukin. Amtagvi is a tumor-infiltrating lymphocyte therapy approved for certain patients with advanced melanoma. Proleukin is used to treat adults with kidney cancer as well as metastatic melanoma. "Increasing patient demand and our current manufacturing schedule provide strong visibility into our third and fourth quarter revenues," said Frederick Vogt, Interim President and CEO. Goldman Sachs recently resumed coverage of Iovance with a 'Buy' rating and $15 price target, saying operational and logistical challenges surrounding the Amtagvi launch are beginning to ease and should support better gross margins. Pipeline looks beyond melanoma. Iovance is trying to expand lifileucel beyond its current melanoma indication. The company is running the Tilvance-301 Phase 3 study of lifileucel plus Merck's Keytruda as a first-line treatment for advanced melanoma. Its pipeline also includes registrational programs evaluating lifileucel in non-small cell lung cancer and endometrial cancer. Iovance ended Q2 with about $243 million in cash, cash equivalents and investments. The company said it has been working to reduce expenses and improve manufacturing efficiency. The company expects to report its third-quarter (Q3) results in early November. Retail sees upside in lung cancer treatment. Retail sentiment surrounding IOVA on Stocktwits remained 'bullish' over the past 24 hours, amid 'high' message volumes. One user highlighted the company's potential opportunity in lung cancer treatment. View this Stocktwits post Another user said positive lung cancer data will take the stock to $20. It is currently trading at $13.3. View this Stocktwits post The stock has surged around 425% so far this year. Also read: QURE Stock Is On Track To Shed About Half Its Market Cap Despite Encouraging Huntington's Disease Data - Here's What Investors Need To Know For updates and corrections, email newsroom[at]stocktwits[dot]com< Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business. 0 Comments / 0 New